OphthaliX updates website to reflect proposed acquisition of Israel-based Improved Vision Systems

OphthaliX Inc. (OTCQB: OPLI), a clinical-stage company focused on developing products that treat and improve sight for people living with ophthalmic disorders, and a subsidiary of Can-Fite BioPharma Ltd. (NYSE MKT: CANF), announced today it has launched an updated website, www.ophthaliX.com, to reflect its definitive agreement to acquire Israel-based Improved Vision Systems Ltd. (I.V.S.).

Upon completion of the acquisition of I.V.S., which is subject to the satisfaction of certain closing conditions, OphthaliX's portfolio of products in development will include two medical devices, Glance™, a desktop application, and vView™, wearable virtual reality goggles. These devices are based on breakthrough technologies that aim to diagnose, improve sight and offer therapy for a variety of ocular diseases and eye conditions including age related macular degeneration (AMD), glaucoma, diabetic retinopathy and oculo-motor pathologies.

OphthaliX continues to develop its drug candidate, CF101, a novel first in class small molecule orally bioavailable drug for ophthalmic indications, glaucoma and uveitis.